CooperSurgical Expands Fertility, Labor & Delivery With $1.6B Acquisition Deal

CooperCompanies COO has agreed to acquire Generate Life Sciences for $1.6 billion.
Privately held Generate Life Sciences provides donor egg & sperm for fertility treatments, fertility cryopreservation services, and newborn stem cell storage (cord blood & cord tissue).
“This acquisition is a strong strategic fit for CooperSurgical,” said Al White, Cooper’s President, and CEO.
The transaction is anticipated to close in Cooper’s Q1 of FY22.
Generate Life Sciences reported approximately $250 million in trailing twelve-month revenues as of September 30, 2021.
The acquisition is expected to be accretive to Cooper’s non-GAAP EPS by approximately $0.30 in the first year after closing.
See the related presentation here.
Price Action: COO shares are down 2.10% at $425 during the premarket session on the last check Thursday.